Theratechnologies, Inc.

Theratechnologies Inc. has agreed to be acquired by CB Biotechnology, LLC for $3.01 per share in cash plus contingent value rights worth up to $1.19 per share.

Peptide drug conjugates represent a novel targeted therapy approach that combines disease-targeting peptides with small molecule drugs to deliver treatments directly to diseased tissues while minimizing systemic toxicity.

Theratechnologies has received FDA approval for a Prior Approval Supplement (PAS) for EGRIFTA SV, paving the way for its replacement with the new EGRIFTA WR formulation while ensuring continued distribution of EGRIFTA SV.

Theratechnologies has received FDA approval for EGRIFTA WR™ (tesamorelin F8), a new formulation that requires weekly rather than daily reconstitution for treating excess visceral abdominal fat in adults with HIV and lipodystrophy.

• The FDA is set to decide on Bavarian Nordic's CHIKV VLP vaccine for chikungunya, potentially the first VLP-based option in the U.S. • GSK's ABCWY vaccine, targeting multiple strains of Neisseria meningitidis, awaits FDA decision for primary care and pediatric use. • Innoviva Specialty Therapeutics' zoliflodacin, a novel antibiotic for gonorrhea, is under FDA review amid rising antimicrobial resistance. • Merck's clesrovimab, a monoclonal antibody for COVID-19, is being reviewed by the FDA for pediatric patients.

Theratechnologies' sudocetaxel zendusortide demonstrates favorable tolerability and efficacy signals in heavily pre-treated ovarian cancer patients in a Phase 1b trial.

Theratechnologies has submitted a Prior Approval Supplement (PAS) to the FDA for changes in the manufacturing of EGRIFTA SV®.

Peptide-drug conjugates (PDCs) are emerging as a novel class of cancer therapeutics, offering potential advantages over antibody-drug conjugates (ADCs) due to their smaller size and rapid internalization.